DBL Cisplatin

DBL Cisplatin





Zuellig Pharma
Concise Prescribing Info
Monotherapy or combination therapy for metastatic nonseminomatous germ cell carcinoma, advanced stage refractory ovarian & bladder carcinoma, refractory squamous cell head & neck carcinoma.
Dosage/Direction for Use
Adult & childn 50-100 mg/m2 as single IV infusion every 3-4 wk or 15-20 mg/m2 daily as slow IV infusion for 5 days every 3-4 wk.
Hypersensitivity to cisplatin- or platinum-containing compd. Hearing disorders, bone marrow depression. Renal impairment. Pregnancy & lactation.
Special Precautions
Anaphylactic-like reactions, history of atopy. Myelosuppression; anaemia; nausea, vomiting; ototoxicity; hypomagnesaemia & hypocalcaemia; peripheral neuropathy, postural hypotension, myasthenic syndromes, seizures, loss of vision; CV toxicity. Ensure adequate hydration to minimise risk of nephrotoxicity. Monitor renal function including GFR, BUN, serum creatinine & CrCl, electrolytes, auditory function, RBC, WBC, platelets, liver function & neurological status prior to & during treatment. Not to be used w/ live vaccines. Hepatic & renal impairment, preexisting hepatic & renal dysfunction. May affect male & female fertility. Women of childbearing potential should use effective contraception. Not recommended during pregnancy. Not to be used during lactation.
Adverse Reactions
Severe nausea & vomiting; renal & urinary disorders; mild bone marrow toxicity; anaphylactic & anaphylactic-like reactions eg, flushing, facial oedema, wheezing, tachycardia, hypotension; tinnitus &/or hearing loss; autonomic neuropathy, seizures, slurred speech, loss of taste & memory, CVA; retinal & pulmonary toxicity; CV abnormalities; VTE; mild alopecia; myalgia; electrolyte disturbances; pyrexia, local effects eg, phlebitis, cellulitis, skin necrosis.
Drug Interactions
Exacerbated nephrotoxic & ototoxic effects w/ aminoglycosides or loop diuretics. Increased hearing loss w/ ifosfamide. Reduced lithium blood levels. Subtherapeutic plasma levels of anticonvulsants. Monitor international normalised ratio w/ anticoagulants eg, coumarins, warfarin. Reduced clearance & intensified neurotoxicity of paclitaxel. Black precipitate w/ Al.
MIMS Class
Cytotoxic Chemotherapy
ATC Classification
L01XA01 - cisplatin ; Belongs to the class of platinum-containing antineoplastic agents. Used in the treatment of cancer.
DBL Cisplatin inj 1 mg/mL
50 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in